Develops drugs for autoimmune and inflammatory disorders.
Dec 2024Revenue $41.1M/yrExpenses $49.4M/yr
No trendCash runway ≈ 2.8 years from Jun 2026
Figures by year
When will Equillium be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $41.1M and expenses $49.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $41.1M | $49.4M | −$8.27M |
| Dec 2023 | $36.1M | $50.6M | −$14.5M |
| Dec 2022 | $15.8M | $77.8M | −$62.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.